<SEC-DOCUMENT>0001104659-25-066378.txt : 20250708
<SEC-HEADER>0001104659-25-066378.hdr.sgml : 20250708
<ACCEPTANCE-DATETIME>20250708141155
ACCESSION NUMBER:		0001104659-25-066378
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250708
DATE AS OF CHANGE:		20250708

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aptevo Therapeutics Inc.
		CENTRAL INDEX KEY:			0001671584
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811567056
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89584
		FILM NUMBER:		251110596

	BUSINESS ADDRESS:	
		STREET 1:		2401 4TH AVE.
		STREET 2:		SUITE 1050
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98121
		BUSINESS PHONE:		206-838-0500

	MAIL ADDRESS:	
		STREET 1:		2401 4TH AVE.
		STREET 2:		SUITE 1050
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98121

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			YA II PN, Ltd.
		CENTRAL INDEX KEY:			0001463928
		ORGANIZATION NAME:           	
		EIN:				980615492
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		1012 SPRINGFIELD AVENUE
		CITY:			MOUNTAINSIDE
		STATE:			NJ
		ZIP:			07092
		BUSINESS PHONE:		201 985 8300

	MAIL ADDRESS:	
		STREET 1:		1012 SPRINGFIELD AVENUE
		CITY:			MOUNTAINSIDE
		STATE:			NJ
		ZIP:			07092

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YA GLOBAL MASTER SPV, LTD.
		DATE OF NAME CHANGE:	20130604

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YA GLOBAL MASTER SPV LLC
		DATE OF NAME CHANGE:	20090512
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: YA II PN, Ltd. -->
          <cik>0001463928</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/16/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001671584</issuerCik>
        <issuerName>Aptevo Therapeutics Inc.</issuerName>
        <issuerCusip>03835L504</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>2401 4th Avenue, Suite 1050</com:street1>
          <com:city>Seattle</com:city>
          <com:stateOrCountry>WA</com:stateOrCountry>
          <com:zipCode>98121</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>YA II PN, Ltd.</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>YA Global Investments II (U.S.), LP</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Yorkville Advisors Global, LP</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Yorkville Advisors Global II, LLC</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>YAII GP, LP</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>YAII GP II, LLC</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Mark Angelo</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>NJ</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>SC-Sigma Global Partners, LP</reportingPersonName>
      <memberGroup>a</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>357842.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>357842.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>357842.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,581,998 shares of Common Stock, consisting of 3,224,156 shares of Common Stock outstanding as reported by Aptevo Therapeutics Inc. (the "Issuer") on June 20, 2025, and an additional 357,842 shares of Common Stock that the reporting person has the right to acquire pursuant to the Standby Equity Purchase Agreement entered into on June 16, 2025 by YA II PN, Ltd. with the Issuer.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Aptevo Therapeutics Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2401 4th Avenue, Suite 1050 Seattle, WA, 98121</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>YA II PN, Ltd.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>1012 Springfield Ave., Mountainside, NJ 07092</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Cayman Islands</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>OO</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>357,842</amountBeneficiallyOwned>
        <classPercent>9.99</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>357,842</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>357,842</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>N</notApplicableFlag>
        <identificationAndClassificationOfGroupMembers>YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with Aptevo Therapeutics Inc. (the "Issuer"), on June 16, 2025. Under the SEPA, the Issuer has the option to sell up to $25 million of its Common Stock to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of shares of Common Stock then beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding shares of Common Stock of the Issuer.

YA II is beneficially owned by YA Global Investments II (U.S.), LP (the "YA Feeder"). Yorkville Advisors Global, LP (the "YA Advisor") is the investment manager to YA II. Yorkville Advisors Global II, LLC (the "YA Advisor GP") is the general partner to the YA Advisor. YAII GP, LP (the "YA GP") is the general partner to the YA Feeder. YAII GP II, LLC (the "Yorkville GP") is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares.

YAII GP, LP is the general partner of SC-Sigma Global Partners, LP ("SC-Sigma"), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares.

For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.</identificationAndClassificationOfGroupMembers>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>YA II PN, Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Gonzalez</signature>
        <title>David Gonzalez, General Counsel</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>YA Global Investments II (U.S.), LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Gonzalez</signature>
        <title>David Gonzalez, General Counsel</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Yorkville Advisors Global, LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Gonzalez</signature>
        <title>David Gonzalez, General Counsel</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Yorkville Advisors Global II, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Gonzalez</signature>
        <title>David Gonzalez, General Counsel</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>YAII GP, LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Gonzalez</signature>
        <title>David Gonzalez, General Counsel</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>YAII GP II, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Gonzalez</signature>
        <title>David Gonzalez, General Counsel</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Mark Angelo</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Mark Angelo</signature>
        <title>Mark Angelo</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>SC-Sigma Global Partners, LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ David Gonzalez</signature>
        <title>David Gonzalez, General Counsel</title>
        <date>06/24/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
